MN-166 (ibudilast) - (SEANOBI)(NIH EAP)

July 15, 2026: MediciNova, Inc. (NASDAQ: MNOV; TSE: 4875) reported it has reached target enrollment of 200 patients in the NIH/NINDS-funded SEANOBI-ALS expanded access study (NCT06743776) evaluating MN‑166 (ibudilast) in amyotrophic lateral sclerosis (ALS). The SEANOBI program, supported under ACT for ALS, is intended to provide access to MN‑166 for people with ALS who are not eligible for ongoing randomized clinical trials.

The company said active participants remain on track with treatment and protocol-specified follow-ups. Final patient follow-ups are projected to conclude in early 2027, after which data analysis will begin to support upcoming scientific presentations and peer-reviewed publications led by an academic investigator.

The release also notes that MediciNova completed enrollment in its COMBAT-ALS Phase 2b/3 trial of MN‑166 in September 2025. MN‑166 has FDA and EMA orphan designation for ALS and FDA Fast Track designation for ALS (as stated).